{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:29:16Z","timestamp":1781659756093,"version":"3.54.5"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a rare autosomal recessive condition characterized by cortisol deficiency and excess androgen production. The current standard of care is glucocorticoid (GC) therapy, and sometimes mineralocorticoids, to replace endogenous cortisol deficiency; however, supraphysiologic GC doses are usually needed to reduce excess androgen production. Monitoring\/titrating GC treatment remains a major challenge, and there is no agreement on assessment of treatment adequacy. This study surveyed expert opinions on current treatment practices and unmet needs in adults with classic CAH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A modified two-round Delphi process with adult endocrinologists was conducted <jats:italic>via<\/jats:italic> online questionnaire. Survey questions were organized into three categories: practice characteristics\/CAH experience, GC management, and unmet needs\/complications. Anonymized aggregate data from Round 1 were provided as feedback for Round 2. Responses from both rounds were analyzed using descriptive statistics. Consensus was defined <jats:italic>a priori<\/jats:italic> as: full consensus (100%, n=9\/9); near consensus (78% to &amp;lt;100%, n=7\/9 or 8\/9); no consensus (&amp;lt;78%, n&amp;lt;7\/9).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The same nine panelists participated in both survey rounds; five (56%) were based in North America and four (44%) in Europe. Most panelists (78%) used hydrocortisone in the majority of patients, but two (22%) preferred prednisone\/prednisolone. Panelists agreed (89%) that adequate control is best evaluated using a balance of clinical presentation and androgen\/precursor laboratory values; no consensus was reached on optimal timing of collecting samples for androgen testing or laboratory values indicating good control. Despite lack of consensus on many aspects of CAH management, panelists agreed on the importance of many disease- and GC-related complications, and that there is a large unmet need for new treatments. With currently available treatments, panelists reported that 46% of classic CAH patients did not have optimized androgen levels, regardless of GC dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The limited areas of consensus obtained in this study reflect the variability in treatment practices for adults with classic CAH, even among clinicians with expertise in treating this population. However, all panelists agreed on the need for new treatments for classic CAH and the importance of many disease- and GC-related complications, which are difficult to manage with currently available treatments.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.1005963","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T15:07:07Z","timestamp":1668784027000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment patterns and unmet needs in adults with classic congenital adrenal hyperplasia: A modified Delphi consensus study"],"prefix":"10.3389","volume":"13","author":[{"given":"Richard J.","family":"Auchus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Courtillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Dobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diala","family":"El-Maouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Falhammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Anatchkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Cutts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuck","family":"Yonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lamotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Touraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1210\/endrev\/bnab016","article-title":"Congenital adrenal hyperplasia - current insights in pathophysiology, diagnostics and management","volume":"43","author":"Claahsen-van der Grinten","year":"2022","journal-title":"Endocr Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1909786","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"383","author":"Merke","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An endocrine society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-00136","article-title":"Glucocorticoid regimens in the treatment of congenital adrenal hyperplasia: A systematic review and meta-analysis","volume":"3","author":"Whittle","year":"2019","journal-title":"J Endocr Soc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00655-w","article-title":"Management challenges and therapeutic advances in congenital adrenal hyperplasia","volume":"18","author":"Mallappa","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S2213-8587(13)70007-X","article-title":"One hundred years of congenital adrenal hyperplasia in Sweden: A retrospective, population-based cohort study","volume":"1","author":"Gidl\u00f6f","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2015.02.002","article-title":"Adrenal steroidogenesis and congenital adrenal hyperplasia","volume":"44","author":"Turcu","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jsbmb.2015.05.013","article-title":"The next 150 years of congenital adrenal hyperplasia","volume":"153","author":"Turcu","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1055\/a-0820-2085","article-title":"Review of health problems in adult patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"127","author":"Reisch","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000625","article-title":"Clinical outcomes in 21-hydroxylase deficiency","volume":"28","author":"Nordenstrom","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-0787","article-title":"Effects of mitotane on testicular adrenal rest tumors in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: A retrospective series of five patients","volume":"184","author":"Bachelot","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1807486","article-title":"Adrenal crisis","volume":"381","author":"Rushworth","year":"2019","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/med.0000000000000308","article-title":"Growth and development in children with classic congenital adrenal hyperplasia","volume":"24","author":"Bonfig","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13086","article-title":"Hypertension in children with congenital adrenal hyperplasia","volume":"85","author":"Maccabee-Ryaboy","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13313","article-title":"Obesity in children with congenital adrenal hyperplasia in the Minnesota cohort: Importance of adjusting body mass index for height-age","volume":"86","author":"Sarafoglou","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jpeds.2014.01.011","article-title":"Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-the Minnesota cohort","volume":"164","author":"Sarafoglou","year":"2014","journal-title":"J Pediatr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2015-2093","article-title":"Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: A Swedish population-based national cohort study","volume":"100","author":"Falhammar","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00493","article-title":"Bone mineral density in adults with congenital adrenal hyperplasia: A systematic review and meta-analysis","volume":"11","author":"Rangaswamaiah","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab712","article-title":"Increased prevalence of fractures in congenital adrenal hyperplasia: A Swedish population-based national cohort study","volume":"107","author":"Falhammar","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0917","article-title":"Health status of adults with congenital adrenal hyperplasia: A cohort study of 203 patients","volume":"95","author":"Arlt","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2013.239","article-title":"Treatment and health outcomes in adults with congenital adrenal hyperplasia","volume":"10","author":"Han","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-011-9591-x","article-title":"Clinical outcomes in the management of congenital adrenal hyperplasia","volume":"41","author":"Falhammar","year":"2012","journal-title":"Endocrine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31431-9","article-title":"Congenital adrenal hyperplasia","volume":"390","author":"El-Maouche","year":"2017","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7393.816","article-title":"Research methods used in developing and applying quality indicators in primary care","volume":"326","author":"Campbell","year":"2003","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.74.9.979","article-title":"Consensus methods: Characteristics and guidelines for use","volume":"74","author":"Fink","year":"1984","journal-title":"Am J Public Health"},{"key":"B26","volume-title":"The Delphi method: Techniques and applications","author":"Linstone","year":"1975"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7275\/pdz9-th90","article-title":"The Delphi technique: Making sense of consensus","volume":"12","author":"Hsu","year":"2007","journal-title":"Pract Assess Res Eval"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.arthro.2017.11.022","article-title":"Expert opinion is necessary: Delphi panel methodology facilitates a scientific approach to consensus","volume":"34","author":"Hohmann","year":"2018","journal-title":"Arthroscopy"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.02.014","article-title":"The use of Multivitamin\/Multimineral supplements: A modified Delphi consensus panel report","volume":"40","author":"Blumberg","year":"2018","journal-title":"Clin Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10m06438","article-title":"An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method","volume":"72","author":"Gurrera","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"19cs12983","DOI":"10.4088\/JCP.19cs12983","article-title":"A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia","volume":"81","author":"Caroff","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1186\/s12913-018-3386-1","article-title":"Development of key interventions and quality indicators for the management of an adult potential donor after brain death: A rand modified Delphi approach","volume":"18","author":"Hoste","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S138867","article-title":"Self-management behaviors to reduce exacerbation impact in copd patients: A Delphi study","volume":"12","author":"Korpershoek","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"Cd012517","DOI":"10.1002\/14651858.CD012517.pub2","article-title":"Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia","volume":"3","author":"Ng","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2102","article-title":"Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia","volume":"97","author":"Finkielstain","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-1249","article-title":"International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: Data from the I-cah registry","volume":"184","author":"Bacila","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1177\/2042018818821294","article-title":"Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency","volume":"10","author":"Oprea","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13492-7","article-title":"Adrenal insufficiency","volume":"361","author":"Arlt","year":"2003","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.3.6462","article-title":"Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia","volume":"85","author":"Merke","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(05)80128-3","article-title":"Cortisol production rate in childhood and adolescence","volume":"117","author":"Linder","year":"1990","journal-title":"J Pediatr"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa202","article-title":"Potential transcriptional biomarkers to guide glucocorticoid replacement in autoimmune addison's disease","volume":"5","author":"Saevik","year":"2021","journal-title":"J Endocr Soc"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1916","article-title":"A phase 2 study of continuous subcutaneous hydrocortisone infusion in adults with congenital adrenal hyperplasia","volume":"101","author":"Nella","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab051","article-title":"Modified-release hydrocortisone in congenital adrenal hyperplasia","volume":"106","author":"Merke","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3809","article-title":"A phase 2 study of chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia","volume":"100","author":"Mallappa","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00217","article-title":"Bilateral adrenalectomy in congenital adrenal hyperplasia: A systematic review and meta-analysis","volume":"103","author":"MacKay","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2298","article-title":"Use of Pet\/Ct with cosyntropin stimulation to identify and localize adrenal rest tissue following adrenalectomy in a woman with congenital adrenal hyperplasia","volume":"97","author":"Crocker","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1258","article-title":"Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency","volume":"99","author":"Auchus","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab749","article-title":"Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia","volume":"107","author":"Auchus","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab438","article-title":"Tildacerfont in adults with classic congenital adrenal hyperplasia: Results from two phase 2 studies","volume":"106","author":"Sarafoglou","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1005963\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T15:07:12Z","timestamp":1668784032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1005963\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":49,"alternative-id":["10.3389\/fendo.2022.1005963"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1005963","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"article-number":"1005963"}}